Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 4/20 | 0.38 |
| ▸ | MMP13 | P45452 | 4/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PGD | P52209 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13991523 | 0.90 | SLC22A6 (0.46) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL21654291 | 0.90 | SLC22A6 (0.46) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL26138089 | 0.83 | SLC22A6 (0.75) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL3089526 | 0.80 | SLC22A6 (0.71) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL27544066 | 0.79 | SLC22A6 (0.55) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL9200070 | 0.77 | BHMT (0.43) | SLC22A6RIPK1 | |
| SCHEMBL8896856 | 0.77 | RIPK1 (0.44) | RIPK1ACACBACACA | |
| SCHEMBL16600523 | 0.76 | SLC22A6 (0.57) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL665350 | 0.76 | SLC22A6 (0.57) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL597917 | 0.76 | GPR84 (0.59) | SLC22A6GPR84MAPTGABRR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903233-B2 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20030225301-A1 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1344763-A1 | Process for producing optically active 3-halogenocarboxylic acid esters and 3-azide-carboxylic acid esters | Takasago International Corporation (JP) | 2003-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225301-A1 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | HDHD5, APEH, AOC3 | SLC22A6 1264/4885GPR84 3209/4885MAPT 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.